Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Integrated DNA Technologies and Elegen Partner to Revolutionize Long DNA Synthesis Market

    Apr 3, 2025, 12:56 PM by
    Strategic partnership marks launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb
    Full story
  • New Research from eClinical Solutions Details Increased Focus on Risk-Based Strategies and Highlights AI Adoption Among Clinical Trial Leaders in 2025

    Apr 3, 2025, 12:56 PM by
    Company prioritizes industry insights on key themes to transform clinical research through innovation in annual Industry Outlook report
    Full story
  • AI Innovations in Laboratory Waste Management as UMass and Cornell Researchers Advance Recycling and Sustainable Plastics

    Apr 3, 2025, 12:53 PM by
    Full story
  • Startup ProFuse Launches Pioneering Drug Discovery Platform for the Prevention of Muscle Loss

    Apr 3, 2025, 12:49 PM by
    Israeli startup ProFuse has launched a new drug discovery platform to develop therapies that prevent muscle loss associated with GLP-1 weight-loss drugs, aging, and cancer. The platform uses lab-grown, highly mature human muscle tissues and automated screening to identify promising drug candidates, reducing reliance on animal testing and accelerating development timelines. The company also announced the appointment of veteran life sciences investor Anat Naschitz to its board.
    Full story
  • Clearwater Publishes Cyber Risk Benchmark Trend Report for Healthcare Vulnerability Management

    Apr 3, 2025, 12:49 PM by
    Full story
  • AES Cleanroom Technology introduces Omni ASCENT: a breakthrough in cleanroom utility integration at INTERPHEX 2025

    Apr 3, 2025, 12:47 PM by
    Full story
  • United Laboratories Offers Up to $2B for Experimental Drug Rights; Novo Nordisk to Pay $2B in Milestones & Royalties

    Apr 3, 2025, 12:46 PM by
    The Chinese pharmaceutical business United Laboratories International offered the Danish manufacturer up to $2 billion for the rights to an experimental medicine. In addition to tiered royalties, Novo Nordisk will make milestone payments of up to $1.8 billion and an upfront payment of $200 million.
    Full story
  • Evaluating the Benefits and Risks of Weight Loss Drugs

    Apr 3, 2025, 01:00 AM by User Not Found
    Bio-IT World| Weight loss medications are in “skyrocketing” utilization. Yet there have been no comprehensive investigations or studies on the effectiveness and risks of glucagon-like peptide-1 receptor agents (GLP-1RA). Researchers at the WashU Medicine collaborated with the Veterans Affairs (VA) St. Louis Health Care System to examine and evaluate more than two million people with diabetes taking popular weight loss drugs such as Ozempic.
    Full story
  • Large Genetic Study Further Untangles the Height-Health Connection

    Apr 2, 2025, 01:00 AM by User Not Found
    Bio-IT World| In the largest phenome wide association study across diverse population groups, an international team of researchers have identified 254 statistically significant associations between genetically explained height and various diseases. Genetically predicted height was linked with decreased risk of 90 diseases and increased risk of 164 others, most notably atrial fibrillation, and a series of conditions involving mental health and the endocrine system that have not been previously described.
    Full story
  • CluePoints Appoints Usama Dar as Chief Product and Technology Officer

    Apr 1, 2025, 11:38 AM by
    CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer.
    Full story
  • Association for Molecular Pathology Celebrates U.S. District Court’s Decision to Vacate FDA Rule on Laboratory-Developed Test Procedure Regulation

    Apr 1, 2025, 11:38 AM by
    AMP announced a favorable ruling in its lawsuit against the U.S. FDA over the regulation of laboratory-developed test procedures.
    Full story
  • Inspira Health Network Expands Utilization of the DoseMeRx Platform

    Apr 1, 2025, 11:38 AM by
    DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced Inspira has expanded the implementation of the dosing platform to serve the newly acquired Mannington site. Inspira has used DoseMeRx since 2020 and integrates with EHR software for faster, efficient access to patient profiles for overall better quality of care.
    Full story
  • Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

    Apr 1, 2025, 11:38 AM by
    Full story
  • Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

    Apr 1, 2025, 11:38 AM by
    First multiplexed solution introduced with the next-generation Cyto-Mine Chroma platform for more efficient biotherapeutic development Utilizes advanced picodroplet microfluidics technology to integrate analysis of antibody productivity and cell viability of monoclonal antibody producing cells
    Full story
  • Bio-IT World Best of Show Finalists Named

    Mar 28, 2025, 01:00 AM by User Not Found
    Bio-IT World| Finalists have been named for the 2025 Bio-IT World Best of Show Awards program. More than 20 new products will be on display next week at the Bio-IT World Conference & Expo. New products will be on display from Artificial, Boulder BioComputing, Copyright Clearance Center, Chemspace, Dantech Corporation, Discngine, expert.ai, Genomenon, Globus, GRAU DATA, iuvo, Komprise, Orchestra Bio, Quantum Corporation, QuartzBio, Sinequa, Tech Mahindra, TetraScience, The Hyve, and Velsera.
    Full story
  • Andaman7 Seeks $5m to Continue Investment in Pioneering Technology

    Mar 27, 2025, 08:13 AM by
    Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.
    Full story
  • Inizio Medical Launches iON.AI to Transform Medical Affairs Capabilities

    Mar 27, 2025, 08:13 AM by
    Full story
  • Mayo Clinic Laboratories and Amprion announce collaboration to advance neurodegenerative disease diagnostics

    Mar 27, 2025, 08:12 AM by
    Mayo Clinic Laboratories and Amprion announced a strategic collaboration to expand access to Amprion’s SAAmplify™–αSYN (CSF) test across the U.S.
    Full story
  • Pistoia Alliance Reducing Carbon Footprint, Thermo Fisher Next-Gen Hybrid Capture Assay, More

    Mar 27, 2025, 01:00 AM by User Not Found
    Bio-IT World| The Pistoia Alliance launched the next phase of its project to measure and reduce the carbon footprint of clinical trials; the Lupus Research Alliance announced the inaugural recipients of the new Targeted Research Program on Engineered Cell Therapies for Lupus; and more.
    Full story
  • Follow the Money: Gene Editing Therapeutics, Breast Cancer AI Predictive Platform, More

    Mar 26, 2025, 01:00 AM by User Not Found
    Bio-IT World| Arbor Biotechnologies will advance its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system; Ataraxis AI will further the development of Ataraxis Breast, the world’s first AI-native prognostic/predictive platform for breast cancer; and more.
    Full story
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy